Congratulations to Respirio Pty Ltd, an FB Rice client, for successfully obtaining a grant from Commericialisation Australia for its project on the rapid identification of Influenza using a test device.

 

The Commercialisation Australia grant will provide Respirio Pty Ltd with funding to provide a clinical accuracy of the test and thus determine the commercial value of the device.

 

FB Rice is proud to be working with Respirio in protecting its innovative advancements in the biotechnology industry and is excited for the outcome of this project.

 

For more information on Commercialisation Australia, click here.

For more information on our Medical Technology team, click here.